Диссертация (1141158), страница 21
Текст из файла (страница 21)
Mitchell P.B., Wilhelm K., Parker G., Austin M.P., Rutgers P., Malhi G.S.. Theclinical features of bipolar depression: a comparison with matched majordepressive disorder patients. J Clin Psychiatry. 2001;62(3):212-216; quiz 217.125165. Mitchell P.B., Hadzi-Pavlovic D., Evoniuk G., Calabrese J.R., Bowden C.L. Afactor analytic study in bipolar depression, and response to lamotrigine. CNSSpectr.
2013;18(4):214-224.166. Montgomery S.A.. Long-term treatment with SSRIs. Clin Neuropharmacol.1992;15(1A):450-451.167. Motovsky B., Pecenak J. Psychopathological characteristics of bipolar andunipolar depression - potential indicators of bipolarity. Psychiatr Danub.2013;25(1):34-39.168.
Nemeroff C.B., Evans D.L., Guyulai L. et al. Double-blind, placebo controlledcomparison of imipramine and paroxetine in the treatment of bipolar depression.Am J Psychiatry. 2001;158(6):906-912.169. Neumann J., Siedel K., Wunderlich H. Anticonvulsants in affective disorders.Amsterdam Oxford Princeton: Experta Medica. 1984:1160-1166.170. Olie J.P., Costa e Silva, Macher J.P. Neuroplasticity. A new approach to thepathophysiology of depression.
Science Press, London, 2004.171. Parker G., Malhi G. Are atypical antipsychotic drugs also atypicalantidepressants? Aust N Z J Psychiatry. 2001;35(5):631-638.172. Parker G., McCraw S., Hadzi-Pavlovic D., Hong M., Barrett M. Bipolardepression: prototypically melancholic in its clinical features. J Affect Disord.2013;147(1-3):331-337.173. Peet M. Induction of mania with selective serotonin re-uptake inhibitors andtricyclic antidepressants. Br J Psychiatry. 1994;164(4):549-550.174. Perlis R.H., Brown E., Baker R.W. et al. Clinical features of bipolar depressionversus major depressive disorder in large multicenter trials.
Am J Psychiatry.2006;163:225-231.175. Perris C. A study of bipolar (manic-depressive) and unipolar recurrentdepressive psychoses. Introduction. Acta Psychiatr Scand Suppl. 1966;194:9-14.126176. Pfizer Inc. A Six-Week Study Evaluating the Efficacy and Safety of GEODONin Patients With a Diagnosis of Bipolar I Depression. ClinicalTrials.gov.Bethesda, MD: National Institutes of Health, 2009.177. Post P.M., Unde T.W., Poy-Byrne P.P. et al. Antidepressant effects ofcarbamazepine. Am J Psychiatry. 1986;143:29-34.178.
Post R.M., Altshuler L.L., Leverich G.S., Frye M.A., Nolen W.A., Kupka R.W.,Suppes T., McElroy S., Keck P.E., Denicoff K.D., Grunze H., Walden J., KitchenC.M.., Mintz J. Mood switch in bipolar depression: comparison of adjunctivevenlafaxine, bupropion and sertraline. Br. J. Psychiatry. 2006;189:124-131.179. Post R.M., Leverich G.R., Nolen W.A. et al. A reevaluation of the role ofantidepressants in the treatment of bipolar depression: data from the StanleyFoundation Bipolar Network. CNS Spectrum. 2003;8(12Suppl4):1-15.180.
Potter W.Z. Bipolar depression: specific treatments. J Clin Psychiatry.1998;59(18):30-36.181. Prien R.F., Klett C.J., Caffey E.M. Lithium carbonate and imipramine in theprevention of affective episodes. Arch Gen Psychiatry. 1973;29:420-425.182. Rapaport M.N., Canuso C.M., Rouillon F., Leblanc J., Young A.H., Loosher A.,Bossie C., Turkoz I., Gharabawi G. Results from the augmentation withrisperidone in resistant depression trial. АРА Annual Meeting, New York,Abstracts NR.
2004. 301 p.183. Richards R., Kinney D.K., Lunde I. et al. Creativity in manic-depressives,cyclothymes, their normal relatives and control subjects. J Abnorm Psychol.1988;97:281-288.184. Robling S.A., Paykel E.S., Dunn V.J. et al. Long-term outcome of severepuerperal psychiatric illness: a 23 year follow-up study. Psychol Med.2000;30:1263-1271.185. Roy-Byrne P., Post R.M., Uhde T.W., Porcu T., Davis D. The longitudinalcourse of recurrent affective illness: life chart data from research patients at theNIMH.
Acta Psychiatr Scand Suppl. 1985;317:1-34.127186. Sachs G. Antidepressants may be useless in bipolar depression. 21st ECNPCongress, Barcelona, Spain, 30 Aug.-3 Sept., 2008.187. Sachs G. Divalproex monotherapy in bipolar depression. Poster presented atAnnual Meeting of the American College of Neuropsychopharmacology, PuertoRico, San Juan, 2001.188. Sachs G. Managing bipolar affective disorder.
London: Science Press, 2004. 146p.189. Sachs G.S. STEP-BD Update: What have we learned, in International BipolarDisorder. Pittsburgh, PA: Western Psychiatric Institute and Clinic, UPMC HealthSystem, 2003.190. Sachs G.S., Altshuler L.L., Ketter T.A. et al. Divalproex versus placebo for thetreatment of bipolar depression. American College of Neuropsychopharmacology.Abstracts.
2001.191. Sachs G.S., Later В., Stoll A.L., Banou M., Triboult A.B., Tohen M.,Honcnhntim J.F. A double-blind trial of bupropion versus desipramine for bipolardepression . J. Clin. Psychiatry. 1994;55:391-393.192. Sachs G.S., Nierenberg A.A., Calabrese J.R. et al. Effectiveness of adjunctiveantidepressanttreatmentforbipolardepression.NEnglJMed.2007;356(17):1711-1722.193.
Salvi V., Fagiolini A., Swartz H.A. et al. The use of antidepressants in bipolardisorder. J Clin Psychiatry. 2008;69(8):1307-1318.194. Simpson S.G., Folstein S.E., Meyers D.A. et al. Bipolar II: The most commonbipolar phenotype? Am J Psychiatr. 1993;150:901-903.195. Stahl S.M., Shelton R.C. Risperidone with and without paroxetine compared toparoxetine alone for bipolar depression. ACNP Annual Meeting, Waikoloa,Hawaii, Abstracts. 2001.
352 p.196. Suppes T., Leverich G.S., Keck P.E. et al. The Stanley Foundation Bipolartreatment outcome Network II. Demographics and illness characteristics of thefirst 261 patients. J Affect Disord. 2001;67:45-59.128197. Suppes T., Webb A., Paul B., Carmody T., Kraemer H., Rush A.J. Clinicaloutcome in a randomized 1-year trial of clozapine versus treatment as usual forpatients with treatment-resistant illness and a history of mania. Am J Psychiatry.1999;156(8):1164-1169.198. SwannA.C., DoughertyD.M., PazzagliaP.J., PhamM., MoellerF.G..Impulsivity: a link between bipolar disorder and substance abuse. BipolarDisord.
2004;6(3):204-212.199. Thase M.E., Jonas A., Khan A. et al. Aripiprazole monotherapy in nonpsychoticbipolar I depression: results of 2 randomized, placebo-controlled studies. J ClinPsychopharmacol. 2008;28(1):13-20.200. Thase M.E., Macfadden W., Weisler R.H.
et al. Efficacy of quetiapinemonotherapy in bipolar I and II depression: a double-blind, placebo-controlledstudy (the BOLDER II study). J Clin Psychopharmacol. 2006;26:600–609.201. Tohen M., Katagiri H., Fujikoshi S., Kanba S. Efficacy of olanzapinemonotherapy in acute bipolar depression: a pooled analysis of controlled studies. JAffect Disord. 2013;149(1-3):196-201.202. Tohen M., Vieta E., Calabrese J.R.
et al. Efficacy of olanzapine and olanzapinefluoxetine combination in the treatment of bipolar depression. Arch GenPsychiatry. 2003;60:1079-1088.203. Tondo L., Baldessarini R.J. Rapid cycling in women and men with bipolarmanic-depressive disorders. Am J Psychiatry. 1998;155:1434-1436.204. Tondo L., Hennen J., Baldessarini R.J. Lower suicidal risk with long-termlithium treatment in major affective illness: A meta-analysis. Acta PsychiatrScand. 2001;104:163-172.205. Tondo L., Hennen J., Baldessarini R.J.
Rapid-cycling bipolar disorder: effects oflong-term treatments. Acta Psychiatr Scand. 2003;108(1):4-14.206. Van der Loos M.L., Mulder P.G., Hartong E.G. et al. Efficacy and safety oflamotrigine as add-on treatment to lithium in bipolar depression: a multi-center,double-blind, placebo-controlled trial.
J Clin Psychiatry. 2009;70:223-231.129207. Vieta E. Managing Bipolar Disorder in Clinical Practice. Published by Currentmedicine group Ltd, Porters South, London, UK, 2006.208. Vieta E., Calabrese J.R., Hennen J., Colom .F, Martínez-Arán A., SánchezMoreno J., Yatham L.N., Tohen M., Baldessarini R.J. Comparison of rapidcycling and non-rapid-cycling bipolar I manic patients during treatment witholanzapine: analysis of pooled data. J Clin Psychiatry. 2004;65(10):1420-1428.209. Vieta E., Valenti M.
Mixed states in DSM-5: Implications for clinical care,education and research. Journal of Affective Disorders. 2013;148:28-36.210. Wehr T.A., Goodwin F.K. Can antidepressants cause mania and worsen thecourse of affective illness? Am J Psychiatry. 1987;144(11):1403-1411.211. Wehr T.A., Goodwin F.K. Rapid cycling in manic-depressive induced bytricyclic antidepressants.
Arch Gen Psychiatry. 1979;36(5):555-559.212. Weisler R.H., Calabrese J.R., Thase M.E., Arvekvist R., Stening G., PaulssonB., Suppes T. Efficacy of quetiapine monotherapy for the treatment of depressiveepisodes in bipolar I disorder: a post hoc analysis of combined results from 2double-blind, randomized, placebo-controlled studies. J Clin Psychiatry.2008;69(5):769-782.213.
Whybrow P.C. A mood apart: Depression, mania and other afflictions of theself. New York: HarperCollins, 1997.214. Winsberg M.E., DeGolia S.G., Strong C.M. et al. Divalproex therapy inmedication-naive and mood-stabilizer-naive bipolar II depression. J AffectDisord. 2001;67(1-3):207-212.215. Yatham L.N., Goldstein J.M., Vieta E. et al. Atypical antipsychotics in bipolardepression: potential mechanisms of action. J Clin Psychiatry. 2005;66:40-48.216. Yatham L.N., Kennedy S.H., Parikh S.V., Schaffer A., Beaulieu S., Alda M.,O'Donovan C., Macqueen G., McIntyre R.S., Sharma V., Ravindran A., YoungL.T., Milev R., Bond D.J., Frey B.N., Goldstein B.I., Lafer B., Birmaher B., HaK., Nolen W.A., Berk M.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
